Key result
Systemic chemotherapy does not significantly alter edoxaban concentrations in colorectal cancer.
Why the study?
Direct oral anticoagulants may have pharmacokinetic drug-drug interactions with anti-cancer agents, but data on edoxaban plasma concentration in patients with colorectal cancer were lacking.
Does concomitant chemotherapy alter edoxaban plasma concentration in patients with colorectal cancer?
Observational (n=26)
Open-label
Yes
Does concomitant chemotherapy alter edoxaban plasma concentration in patients with colorectal cancer?
Concomitant chemotherapy does not significantly alter edoxaban plasma concentrations in patients with colorectal cancer, suggesting minimal drug-drug interactions.
Answers are grounded in this paper and cite their sources.
Edoxaban levels stable with chemotherapy; extends pharmacokinetic data but leaves open larger outcome trials before practice change.
Direct oral anticoagulants are a treatment option for cancer-associated venous thromboembolism (VTE). In patients receiving chemotherapy for cancer, there may be pharmacokinetic drug–drug interaction between anti-cancer agents and direct oral anticoagulants. However, there are no data available in patients with colorectal cancer (CRC). In this study, we investigated edoxaban plasma concentration in patients with CRC receiving chemotherapy. The study included patients with unresectable or metastatic CRC undergoing systemic chemotherapy and simultaneously receiving anticoagulant therapy with edoxaban for VTE or atrial fibrillation. Blood sampling was performed prior to chemotherapy and after 24 h and 48 h depending on the chemotherapy regimen. Data of 21 and 26 patients were analyzed for edoxaban plasma concentration and safety, respectively. Edoxaban plasma concentration was not statistically different before and after 24 h and 48 h between patients receiving treatment with a chemotherapy regimen, cytotoxic drug, and a molecular targeted drug. One patient had major bleeding requiring transfusion; however, edoxaban plasma concentration was not elevated before and 24 h after chemotherapy (19.98 and 9.63 ng/ml, respectively). In patients with CRC, edoxaban plasma concentration did not change after chemotherapy, implying that drug–drug interaction between edoxaban and anti-cancer agents was minimal.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) conducted an observational in Colorectal cancer with venous thromboembolism or atrial fibrillation (n=26). Systemic chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Change in edoxaban plasma concentration utilizing plasma Xa activity before and after chemotherapy (p=>0.05). Concomitant systemic chemotherapy did not significantly alter edoxaban plasma concentrations at 24 and 48 hours in patients with colorectal cancer, indicating minimal drug-drug interactions.
Synapse has enriched 10 related papers. Consider them for comparative context: